| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
cis-Nerolidol targets bacterial cells, exhibiting antibacterial activity. It induces DNA damage and ER stress in cancer cell lines through a mechanism involving cAMP, Ca2+, and MAPK signaling. The compound's antioxidant and trypanocidal activities have also been documented. Its ability to enhance antibiotic efficacy suggests it may target bacterial resistance mechanisms.
|
|---|---|
| ln Vitro |
cis-Nerolidol demonstrates antibacterial activity in vitro. It exhibits anti-cancer activity by inducing DNA damage and ER stress in bladder carcinoma cell lines. The compound has antioxidant and trypanocidal activities. It enhances antibiotic efficacy, making it a compound of interest for antimicrobial research. These activities make cis-nerolidol valuable for research on cancer, infection, and oxidative stress.
|
| ln Vivo |
In vivo activity of cis-nerolidol has been suggested by its antibacterial and anticancer activities. Its ability to enhance antibiotic efficacy suggests potential for combination therapy in vivo. Further in vivo studies are needed to fully characterize its efficacy, pharmacokinetics, and therapeutic potential in various disease models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for cis-nerolidol are not extensively documented. Its effects on cAMP, Ca2+, and MAPK signaling can be assessed using specific assays for these pathways. The compound's antioxidant activity can be measured using DPPH or ABTS assays. Antibacterial activity is evaluated using standard bacterial growth inhibition assays.
|
| Cell Assay |
In vitro cellular assays for cis-nerolidol involve treating cancer cell lines (e.g., bladder carcinoma) with varying concentrations of the compound. DNA damage is assessed using comet assays or γ-H2AX staining. ER stress is evaluated by measuring markers such as CHOP or BiP. Antibacterial activity is assessed using bacterial growth inhibition assays.
|
| Animal Protocol |
In vivo animal experiments for cis-nerolidol are not extensively documented. If used in animal models, typical protocols would involve administering the compound to models of cancer or infection and evaluating efficacy by measuring tumor growth or bacterial load. Further studies are needed to characterize its in vivo efficacy and safety profile.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for cis-nerolidol are limited. As a sesquiterpene alcohol, its absorption, distribution, metabolism, and excretion properties would influence its bioavailability. Further pharmacokinetic studies are needed to determine its systemic exposure and elimination pathways for potential therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for cis-nerolidol are limited. As a natural product-derived compound, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
(6Z)-Nerolidol is a nerolidol in which the double bond at position 6 is in the cis configuration. It has been reported that cis-nerolidol exists in Artemisia Thuscula, Thulinella chrysantha, and other organisms with relevant data. See also: Nerolidol (note moved to).
cis-Nerolidol (CAS#: 3790-78-1) is a naturally occurring sesquiterpene alcohol with antioxidant, antibacterial, anti-cancer, and trypanocidal activities. Its molecular formula is C15H26O with a molecular weight of 222.37. The compound induces DNA damage and ER stress in cancer cells and enhances antibiotic efficacy. |
| Molecular Formula |
C15H26O
|
|---|---|
| Molecular Weight |
222.37
|
| Exact Mass |
222.198
|
| CAS # |
3790-78-1
|
| Related CAS # |
Nerolidol;7212-44-4
|
| PubChem CID |
5320128
|
| Appearance |
Colorless to light yellow ointment
|
| Density |
0.869g/cm3
|
| Boiling Point |
276ºC at 760mmHg
|
| Melting Point |
-98.0 °C (lit.)
|
| Flash Point |
109.9ºC
|
| Index of Refraction |
n20/D 1.478(lit.)
|
| LogP |
4.396
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
16
|
| Complexity |
269
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C/C(=C/CC/C(=C\CCC(C=C)(C)O)/C)/C
|
| InChi Key |
FQTLCLSUCSAZDY-KAMYIIQDSA-N
|
| InChi Code |
InChI=1S/C15H26O/c1-6-15(5,16)12-8-11-14(4)10-7-9-13(2)3/h6,9,11,16H,1,7-8,10,12H2,2-5H3/b14-11-
|
| Chemical Name |
(6Z)-3,7,11-trimethyldodeca-1,6,10-trien-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4970 mL | 22.4850 mL | 44.9701 mL | |
| 5 mM | 0.8994 mL | 4.4970 mL | 8.9940 mL | |
| 10 mM | 0.4497 mL | 2.2485 mL | 4.4970 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
